Summary
Fifty-two patients with rheumatoid arthritis were studied in a single blind trial comparing aurothioglucose and auranofin. The duration of the study was 52 weeks. Twenty-six patients, 13 in each treatment group, dropped out during the first year of treatment. The main reason for discontinuing treatment with aurothioglucose was adverse reactions and, in the auranofin group, lack of efficacy. In those patients who continued therapy the results of treatment were comparable; patients on aurothioglucose improved slightly more than auranofin treated patients, although the difference was not statistically significant.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Forestier. J. Rheumatoid arthritis and its treatment by gold salts. J Lab Glin Med, 1935, 20, 827–829.
Empire Rheumatism Council. Gold therapy in rheumatoid arthritis, final report of a multicentre controlled trial. Ann Rheum Dis, 1961, 20, 315–334.
The Cooperating Clinics Committee of the American Rheumatism Association. A controlled trial of gold salt therapy in rheumatoid arthritis. Arthritis Rheum, 1973, 16, 353–358.
Sigler, J.W., Bluhm, G.B., Duncan, H., Sharp, J.T., Ensign, D.C., McCrum, W.R. Gold salts in the treatment of rheumatoid arthritis. A double blind study. Ann Int Med, 1974, 80, 21–26.
Cats, A. A multicentre controlled trial of the effects of different dosage of gold therapy, followed by a maintenance dosage. Agents Actions. 1976, 6, 355–362.
Walz, D.T., Di Martino, M.J., Chakrin, L.W., Sutton, B.M., Misher, A. Antiarthritic properties and unique pharmacological profile of a potential chrysotherapeutic agent: SK & F D-39162. J Pharmacol Exp Ther, 1976, 197, 142–152.
Finkelstein, A.E., Walz, D.T., Batista, V. Auranofin. New oral gold compound for treatment of rheumatoid arthritis. Ann Rheum Dis, 1976, 35, 251–257.
Berglof, F.E., Berglof, K., Walz, D.T. Auranofin: an oral chrysotherapeutic agent for the treatment of rheumatoid arthritis. J Rheumatol, 1978, 5, 68–74.
Ropes, M.W. Diagnostic criteria for rheumatoid arthritis 1958 revision. Ann Rheum Dis, 1959, 18, 49–51.
Van Riel, P.L.C.M., Gribnau, F.W.J., Van de Putte, L.B.A. Cell-bound gold in patients treated with aurothioglucose and with auranofin. A comparison of different methods of determination. J Rheumatol, 1983, 10, 574–578.
Van Riel, P.L.C.M., Gribnau, F.W.J., Van de Putte, L.B.A., Yap, S.H. Loose stools during auranofin treatment: clinical study and some pathogenetic possibilities. J Rheumatol, 1983, 10, 222–226.
Naranjo, C.A., Busto, U., Sellers, E.M. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 1981, 30, 239–245.
Mallya, R.K., Mace, B.E. The assessment of disease activity in rheumatoid arthritis using a multivariate analysis. Rheumatol Rehabil. 1981, 20, 14–17.
Ward, J.R., Williams, H.J., Egger, M.J., Reading, J.C. et al. Comparison of auranofin, gold sodium thiomalate and placebo in the treatment of active rheumatoid arthritis: response by treatment duration. In: Auranofin. Proceedings of a Smith, Kline & French International Symposium. Editors: Capell, H.A., Cole, D.S., Manghani, K.K., Morris, R.W. Amsterdam. Excerpta Medica 1983, 115–132.
Williams, H.J. A controlled clinical trial of auranofin, gold sodium thiomalate and placebo in rheumatoid arthritis. Arthritis. Arthritis Rheum. 1982, 25/4 (suppl) S68 (Abstract 387).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
van Riel, P.L.C.M., Van De Putte, L.B.A., Gribnau, F.W.J. et al. Comparison of auranofin and aurothioglucose in the treatment of rheumatoid arthritis: a single blind study. Clin Rheumatol 3 (Suppl 1), 51–56 (1984). https://doi.org/10.1007/BF03342622
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03342622